Significant differences in drug susceptibility among species in the Candida parapsilosis group

Diagnostic Microbiology and Infectious Disease

Volumn 62, Issue 1, 2008, Pages 106-109

  van Asbeck, Eveline ^a,b,c,d   Clemons, Karl V ^a,b,c   Martinez, Marife ^a,b,c   Tong, Ann Jay ^a,b,c   Stevens, David A ^a,b,c  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anidulafungin; Candida parapsilosis; Caspofungin; Fluconazole; Susceptibility

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIUM ISOLATE; CANDIDA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DRUG SENSITIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; ECHINOCANDINS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE;

EID: 49549110048     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.04.019     Document Type: Article

References (27)

1. Cappelletty D., and Eiselstein-McKitrick K. The echinocandins. Pharmacother 27 (2007) 369-388
2. Chamilos G., Lewis R.E., Albert N., and Kontoyiannis D.P. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51 (2007) 2257-2259
3. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard-second edition. CLSI document M27-A2 (2002), Clinical and Laboratory Standards Institute, Wayne, PA
4. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
5. Garber G. An overview of fungal infections. Drugs 61 Suppl. 1 (2001) 1-12
6. Krcmery V., and Barnes A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J. Hosp. Infect. 50 (2002) 243-260
7. Lehmann P.F., Lin D., and Lasker B.A. Genotypic identification and characterization of species and strains within the genus Candida by using random amplified polymorphic DNA. J. Clin. Microbiol. 30 (1992) 3249-3254
8. Levin A.S., Costa S.F., Mussi N.S., Basso M., Sinto S.I., Machado C., Geiger D.C., Villares M.C., Schreiber A.Z., Barone A.A., and Branchini M.L. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn. Microbiol. Infect. Dis. 30 (1998) 243-249
9. Levy I., Rubin L.G., Vasishtha S., Tucci V., and Sood S.K. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin. Infect. Dis. 26 (1998) 1086-1088
10. Lin D., Wu L.C., Rinaldi M.G., and Lehmann P.F. Three distinct genotypes within Candida parapsilosis from clinical sources. J. Clin. Microbiol. 33 (1995) 1815-1821
11. Marco F., Pfaller M.A., Messer S.A., and Jones R.N. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 32 (1998) 33-37
12. Melo A.S., Colombo A.L., and Arthington-Skaggs B.A. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob. Agents Chemother. 51 (2007) 3081-3088
13. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., Lupinacci R., Sable C., Kartsonis N., and Perfect J. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347 (2002) 2020-2029
14. Pfaller M.A., and Diekema D.J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40 (2002) 3551-3557
15. Pfaller M.A., and Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20 (2007) 133-163
16. Pfaller M.A., Diekema D.J., Jones R.N., Messer S.A., Hollis R.J., and SENTRY Participants Group. Trends in antifungal susceptibility of Candida spp. Isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40 (2002) 852-856
17. Pfaller M.A., Messer S.A., Boyken L., Rice C., Tendolkar S., Hollis R.J., and Diekma D.J. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol. 42 (2004) 3117-3119
18. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46 (2008) 150-156
19. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., Betts R., Wible M., Goldstein B.P., Schranz J., Krause D.S., and Walsh T.J. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356 (2007) 2472-2482
20. Sarvikivi E., Lyytikainen O., Soll D.R., Pujol C., Pfaller M.A., Richardson M., Koukila-Kahkola P., Luukkainen P., and Saxen H. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J. Clin. Microbiol. 43 (2005) 2729-2735
21. Stevens D.A., Espiritu M., and Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48 (2004) 3407-3411
22. Stevens D.A., Ichinomiya M., Koshi Y., and Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50 (2006) 3160-3161
23. Tavanti A., Davidson A.D., Gow N.A., Maiden M.C., and Odds F.C. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43 (2005) 284-292
24. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., Biraghi E., Canton E., Zimmermann K., Seaton S., Grillot R., and ECMM Working Group on Candidaemia. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 23 (2004) 317-322
25. van Asbeck E.C., Huang Y.C., Markham A.N., Clemons K.V., and Stevens D.A. Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare worker hands as source, and review of published studies. Mycopathol 164 (2007) 287-293
26. van Asbeck E.C., Clemons K.V., Markham A.N., Stevens D.A., and Candida parapsilosis global epidemiology group. Molecular epidemiology of the global and temporal diversity of Candida parapsilosis. Scand J Infect Dis 3 (2008) 1-8
27. Weems J.J., Chamberland M.E., Ward J., Willy M., Padhye A.A., and Solomon S.L. Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J. Clin. Microbiol. 25 (1987) 1029-1032